argenx SE
argenx SE (ARGX) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ARGX · as of Jun 8, 2026
Key Statistics
Explore argenx SE Data
argx stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 36 · Buy rate: 86.1%
The ARGX analyst consensus is Buy, based on ratings from 36 Wall Street analysts over the past 3 months. The average 12-month price target is $1052.00, representing +18.03% upside from the current price of $891.32.
Competitors & Peers
argx competitorsARGX
A
ALC
ALNY
BDX
CAHStock Performance
Full HistoryAbout argenx SE
argenx SE a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lea…
what is argenx se · argx stock overview · argenx se company profile · who is argenx se ceo · argx NASDAQ · argenx se headquarters · argenx se business segments
About Stock Overview & Key Data
argenx SE (ARGX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since May 18, 2017. As of the latest trading session, ARGX stock price is $891.32, with a market capitalization of $55.2B. The stock has returned +52.72% over the past 12 months and +5.99% year-to-date.
According to 36 Wall Street analysts, the consensus rating for argenx SE stock is Buy, with an average 12-month price target of $1052.00. In fiscal year 2025, argenx SE reported revenue of $4.2B and net income of $1.3B. For detailed data — including argenx SE revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, argenx SE (ARGX) stock price is $891.32. The stock is traded on NASDAQ under the ticker symbol ARGX. The 52-week range is $510.06 – $934.62.